Related Experiment Videos

A phase II trial of m-AMSA in patients with small-cell lung cancer

R B Natale, R J Gralla, R E Wittes

    Cancer Clinical Trials
    |January 1, 1981
    PubMed

    Insights

    This study found that amsacrine (m-AMSA) showed no significant therapeutic benefit for patients with small-cell lung cancer. Myelosuppression was a key side effect, limiting further investigation of this chemotherapy in heavily pretreated patients.

    Area of Science:

    • Oncology
    • Pharmacology
    • Cancer Research

    Background:

    • Small-cell lung cancer (SCLC) remains a challenging malignancy with limited treatment options.
    • Developing effective chemotherapy regimens for relapsed or refractory SCLC is a critical unmet need.

    Purpose of the Study:

    • To evaluate the efficacy and safety of amsacrine (m-AMSA) in patients with previously treated small-cell lung cancer.
    • To determine the optimal dose and schedule for m-AMSA in this patient population.

    Main Methods:

    • Eighteen patients with SCLC were enrolled.
    • Patients received intravenous amsacrine (m-AMSA) at doses of 90 mg/m2 or 120 mg/m2 every 3 weeks.
    • Therapeutic responses and dose-limiting toxicities were assessed.

    Main Results:

    • No useful therapeutic responses were observed in 16 patients who received adequate treatment.
    • Myelosuppression was identified as the primary dose-limiting side effect.
    • The drug demonstrated insufficient activity at the tested doses and schedule.

    Conclusions:

    • Amsacrine (m-AMSA) at the studied doses and schedule lacks sufficient activity for small-cell lung cancer.
    • Further investigation of m-AMSA is not warranted in heavily pretreated SCLC patients due to lack of efficacy and significant myelosuppression.

    Related Concept Videos